WATERTOWN, Mass. — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company developing oral small molecule degrader medicines for immunological diseases, said it has closed its upsized underwritten public offering totaling $602.0 million of its common stock.
The company sold and issued 8,050,000 shares of common stock, including 1,050,000 shares sold following the full exercise by underwriters of their option to purchase additional shares. The shares were sold at a public offering price of $86.00 per share.
Gross proceeds from the offering were approximately $692.3 million, before deducting underwriting discounts, commissions and estimated offering expenses payable by Kymera.
Morgan Stanley, J.P. Morgan, Jefferies, Stifel, Guggenheim Securities and Wells Fargo Securities acted as joint book-running managers for the offering.
The securities were offered pursuant to an automatically effective shelf registration statement on Form S-3 (No. 333-282912), which was filed with the U.S. Securities and Exchange Commission (SEC) on October 31, 2024. The offering was made only by means of a prospectus supplement and an accompanying prospectus that form part of the registration statement.
A final prospectus supplement describing the terms of the offering has been filed with the SEC and is available on the SEC’s website. Copies of the final prospectus supplement and the accompanying prospectus may also be obtained from the respective book-running managers.
This announcement does not constitute an offer to sell or a solicitation of an offer to buy any securities, nor will there be any sale of these securities in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under applicable securities laws.
Kymera Therapeutics is a clinical-stage biotechnology company pioneering the field of targeted protein degradation to develop medicines aimed at addressing serious health problems. The company is focused on building a pipeline of oral small molecule degraders designed to target disease pathways that are difficult to address with conventional therapeutics. Founded in 2016, Kymera is headquartered in Watertown, Massachusetts, and has been recognized as one of Boston’s top workplaces in recent years.
